Since vemurafenib is indicated for the treatment of patients with BRAFV600E-positive unresectable or metastatic melanoma, the patient selection process should begin with BRAF mutational analysis of patients’ tumor tissues. The gene discussed is BRAF; the disease is neoplasm.